Evidence Suggesting That Obesity Prevention Measures May Improve Prostate Cancer Outcomes Using Data from a Prospective Randomized Trial

Table 1

Description of the 49 men in the study cohort who underwent sAST stratified by clinical factors at randomization and initial treatment.

Clinical factor
Age, median (IQR), yr	72.0 (68.9, 75.5)
PSA, median (IQR), ng/mL	12.1 (7.90, 20.0)
PSA
<4	3 (6%)
4–10	15 (31%)
10–20	18 (37%)
>20	13 (27%)
Gleason score
5-6	10 (20%)
7	28 (57%)
8–10	11 (22%)
ACE-27 comorbidity score
No or minimal	39 (80%)
Moderate or severe	10 (20%)
1992 AJCC clinical stage
T1c	18 (37%)
T2a	8 (16%)
T2b	23 (47%)
BMI, median (IQR), kg/m^2	27.4 (26.0, 30.2)
BMI
<18.5 (underweight)	0 (0%)
18.5–24.9 (normal)	8 (16%)
25.0–29.9 (overweight)	28 (57%)
≥30.0 (obese)	13 (27%)
Percent positive biopsies, median (IQR)	50.0 (33.3, 66.7)
Percent positive biopsies:
<50%	19 (39%)
≥50%	30 (61%)
2013 NCCN risk group
Low^a or intermediate risk	30 (61%)
High risk	19 (39%)
Initial treatment received
RT only	34 (69%)
RT + AST	15 (31%)

Abbreviations: BMI: body mass index, RT: radiation therapy, AST: androgen suppression therapy, sAST: salvage androgen suppression therapy, ACE: Adult Comorbidity Evaluation, and IQR: interquartile range.
^aAs described in Section 2, men with low risk disease (calculated using PSA level, Gleason score, and clinical stage) were included if they had radiographic evidence of T3 disease (extracapsular extension or seminal vesicle invasion). In this study, two men were included who met these criteria.